1
|
Dickson CF, Hertel S, Tuckwell AJ, Li N, Ruan J, Al-Izzi SC, Ariotti N, Sierecki E, Gambin Y, Morris RG, Towers GJ, Böcking T, Jacques DA. The HIV capsid mimics karyopherin engagement of FG-nucleoporins. Nature 2024; 626:836-842. [PMID: 38267582 PMCID: PMC10881392 DOI: 10.1038/s41586-023-06969-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 12/13/2023] [Indexed: 01/26/2024]
Abstract
HIV can infect non-dividing cells because the viral capsid can overcome the selective barrier of the nuclear pore complex and deliver the genome directly into the nucleus1,2. Remarkably, the intact HIV capsid is more than 1,000 times larger than the size limit prescribed by the diffusion barrier of the nuclear pore3. This barrier in the central channel of the nuclear pore is composed of intrinsically disordered nucleoporin domains enriched in phenylalanine-glycine (FG) dipeptides. Through multivalent FG interactions, cellular karyopherins and their bound cargoes solubilize in this phase to drive nucleocytoplasmic transport4. By performing an in vitro dissection of the nuclear pore complex, we show that a pocket on the surface of the HIV capsid similarly interacts with FG motifs from multiple nucleoporins and that this interaction licences capsids to penetrate FG-nucleoporin condensates. This karyopherin mimicry model addresses a key conceptual challenge for the role of the HIV capsid in nuclear entry and offers an explanation as to how an exogenous entity much larger than any known cellular cargo may be able to non-destructively breach the nuclear envelope.
Collapse
Affiliation(s)
- C F Dickson
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - S Hertel
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - A J Tuckwell
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - N Li
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - J Ruan
- Electron Microscope Unit, Mark Wainwright Analytical Centre, University of New South Wales, Sydney, New South Wales, Australia
| | - S C Al-Izzi
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- School of Physics, University of New South Wales, Sydney, New South Wales, Australia
| | - N Ariotti
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia
| | - E Sierecki
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - Y Gambin
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - R G Morris
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- School of Physics, University of New South Wales, Sydney, New South Wales, Australia
| | - G J Towers
- Infection and Immunity, University College London, London, UK
| | - T Böcking
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - D A Jacques
- Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia.
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia.
| |
Collapse
|
2
|
Basiri M, Ghaffari ME, Ruan J, Murugesan V, Kleytman N, Belinsky G, Akhavan A, Lischuk A, Guo L, Klinger K, Mistry PK. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center. eLife 2023; 12:e87537. [PMID: 37249220 PMCID: PMC10317498 DOI: 10.7554/elife.87537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Accepted: 05/22/2023] [Indexed: 05/31/2023] Open
Abstract
Background A salutary effect of treatments for Gaucher disease (GD) has been a reduction in the incidence of avascular osteonecrosis (AVN). However, there are reports of AVN in patients receiving enzyme replacement therapy (ERT) , and it is not known whether it is related to individual treatments, GBA genotypes, phenotypes, biomarkers of residual disease activity, or anti-drug antibodies. Prompted by development of AVN in several patients receiving ERT, we aimed to delineate the determinants of AVN in patients receiving ERT or eliglustat substrate reduction therapy (SRT) during 20 years in a tertiary referral center. Methods Longitudinal follow-ups of 155 GD patients between 2001 and 2021 were analyzed for episodes of AVN on therapy, type of therapy, GBA1 genotype, spleen status, biomarkers, and other disease indicators. We applied mixed-effects logistic model to delineate the independent correlates of AVN while receiving treatment. Results The patients received cumulative 1382 years of treatment. There were 16 episodes of AVN in 14 patients, with two episodes, each occurring in two patients. Heteroallelic p.Asn409Ser GD1 patients were 10 times (95% CI, 1.5-67.2) more likely than p.Asn409Ser homozygous patients to develop osteonecrosis during treatment. History of AVN prior to treatment initiation was associated with 4.8-fold increased risk of AVN on treatment (95% CI, 1.5-15.2). The risk of AVN among patients receiving velaglucerase ERT was 4.68 times higher compared to patients receiving imiglucerase ERT (95% CI, 1.67-13). No patient receiving eliglustat SRT suffered AVN. There was a significant correlation between GlcSph levels and AVN. Together, these biomarkers reliably predicted risk of AVN during therapy (ROC AUC 0.894, p<0.001). Conclusions There is a low, but significant risk of AVN in GD in the era of ERT/SRT. We found that increased risk of AVN was related to GBA genotype, history of AVN prior to treatment initiation, residual serum GlcSph level, and the type of ERT. No patient receiving SRT developed AVN. These findings exemplify a new approach to biomarker applications in a rare inborn error of metabolism to evaluate clinical outcomes in comprehensively followed patients and will aid identification of GD patients at higher risk of AVN who will benefit from closer monitoring and treatment optimization. Funding LSD Training Fellowship from Sanofi to MB.
Collapse
Affiliation(s)
- Mohsen Basiri
- Department of Internal Medicine, Yale UniversityNew HavenUnited States
| | - Mohammad E Ghaffari
- Department of ENT, Head and Neck Surgery, Guilan University of Medical SciencesRashtIslamic Republic of Iran
| | - Jiapeng Ruan
- Department of Internal Medicine, Yale UniversityNew HavenUnited States
| | | | | | - Glenn Belinsky
- Department of Internal Medicine, Yale UniversityNew HavenUnited States
| | - Amir Akhavan
- Department of Computer and Information Science, University of Massachusetts DartmouthDartmoutUnited States
| | - Andrew Lischuk
- Department of Radiology and Biomedical Imaging, Yale UniversityNew HavenUnited States
| | - Lilu Guo
- Translational Sciences, SanofiFraminghamUnited States
| | | | - Pramod K Mistry
- Department of Internal Medicine, Yale UniversityNew HavenUnited States
| |
Collapse
|
3
|
Zheng Y, Ruan J, Gu S, Yi X, Xu C. MRI Visualization of Bowel Endometriosis: A Pilot Study. J Minim Invasive Gynecol 2022. [DOI: 10.1016/j.jmig.2022.09.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
4
|
Ruan J, Tian Q, Wang Y, Chang K, Yi X. 8659 Interleukin-33 Promotes Endometriosis Fibrosis by Inducing Fibroblast to Myofibroblast Transformation. J Minim Invasive Gynecol 2022. [DOI: 10.1016/j.jmig.2022.09.455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Yuan G, Li R, Zang M, Li Q, Hu X, Fan W, Huang W, Ruan J, Pang H, Chen J. 719P Tyrosine kinase inhibitors and/or immune checkpoint inhibitors is required for improving efficacy of transarterial chemoembolization for hepatocellular carcinoma: A large-scale multicenter real-world study of 582 patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
6
|
Shuaishuai X, Wu W, Chen R, Ye C, Li Q, Chen J, Jiang Q, Ruan J. 62P Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Ye C, Chen R, Jiang Q, Wu W, Yan F, Li Q, Shuaishuai X, Wang Y, Jia Y, Zhang X, Shen P, Ruan J. 915P EMLI-ICC: An ensemble machine learning-based proteome and transcriptome integration algorithm for metastasis prediction and risk-stratification in intrahepatic cholangiocarcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
8
|
Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen TH, Mehta S, Guo L, Kramer ML, Ruan J, Wang H, Davison M, Kumar D, Vidyadhara DJ, Zhang B, Klinger K, Mistry PK. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. eLife 2022; 11:e79830. [PMID: 35972072 PMCID: PMC9381039 DOI: 10.7554/elife.79830] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 07/08/2022] [Indexed: 12/17/2022] Open
Abstract
Background Neuronopathic Gaucher disease (nGD) is a rare neurodegenerative disorder caused by biallelic mutations in GBA and buildup of glycosphingolipids in lysosomes. Neuronal injury and cell death are prominent pathological features; however, the role of GBA in individual cell types and involvement of microglia, blood-derived macrophages, and immune infiltrates in nGD pathophysiology remains enigmatic. Methods Here, using single-cell resolution of mouse nGD brains, lipidomics, and newly generated biomarkers, we found induction of neuroinflammation pathways involving microglia, NK cells, astrocytes, and neurons. Results Targeted rescue of Gba in microglia and neurons, respectively, in Gba-deficient, nGD mice reversed the buildup of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), concomitant with amelioration of neuroinflammation, reduced serum neurofilament light chain (Nf-L), and improved survival. Serum GlcSph concentration was correlated with serum Nf-L and ApoE in nGD mouse models as well as in GD patients. Gba rescue in microglia/macrophage compartment prolonged survival, which was further enhanced upon treatment with brain-permeant inhibitor of glucosylceramide synthase, effects mediated via improved glycosphingolipid homeostasis, and reversal of neuroinflammation involving activation of microglia, brain macrophages, and NK cells. Conclusions Together, our study delineates individual cellular effects of Gba deficiency in nGD brains, highlighting the central role of neuroinflammation driven by microglia activation. Brain-permeant small-molecule inhibitor of glucosylceramide synthase reduced the accumulation of bioactive glycosphingolipids, concomitant with amelioration of neuroinflammation involving microglia, NK cells, astrocytes, and neurons. Our findings advance nGD disease biology whilst identifying compelling biomarkers of nGD to improve patient management, enrich clinical trials, and illuminate therapeutic targets. Funding Research grant from Sanofi; other support includes R01NS110354, Yale Liver Center P30DK034989, pilot project grant.
Collapse
Affiliation(s)
| | - Shiny Nair
- Department of Internal Medicine, Yale School of MedicineNew HavenUnited States
| | - Glenn Belinsky
- Department of Internal Medicine, Yale School of MedicineNew HavenUnited States
| | - Joseph Gans
- Translational Sciences, SanofiFraminghamUnited States
| | - Erin Teeple
- Translational Sciences, SanofiFraminghamUnited States
| | | | - Sameet Mehta
- Yale Center for Genome Analysis, Yale School of MedicineNew HavenUnited States
| | - Lilu Guo
- Translational Sciences, SanofiFraminghamUnited States
| | | | - Jiapeng Ruan
- Department of Internal Medicine, Yale School of MedicineNew HavenUnited States
| | - Honggge Wang
- Translational Sciences, SanofiFraminghamUnited States
| | | | - Dinesh Kumar
- Translational Sciences, SanofiFraminghamUnited States
| | - DJ Vidyadhara
- Department of Neuroscience, Yale School of MedicineNew HavenUnited States
| | - Bailin Zhang
- Translational Sciences, SanofiFraminghamUnited States
| | | | - Pramod K Mistry
- Department of Internal Medicine, Yale School of MedicineNew HavenUnited States
- Department of Molecular & Cellular Physiology, Yale School of MedicineNew HavenUnited States
| |
Collapse
|
9
|
Jarvis J, Lebedev V, Romanov A, Broemmelsiek D, Carlson K, Chattopadhyay S, Dick A, Edstrom D, Lobach I, Nagaitsev S, Piekarz H, Piot P, Ruan J, Santucci J, Stancari G, Valishev A. Experimental demonstration of optical stochastic cooling. Nature 2022; 608:287-292. [PMID: 35948709 PMCID: PMC9365692 DOI: 10.1038/s41586-022-04969-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Accepted: 06/13/2022] [Indexed: 12/02/2022]
Abstract
Particle accelerators and storage rings have been transformative instruments of discovery, and, for many applications, innovations in particle-beam cooling have been a principal driver of that success1. Stochastic cooling (SC), one of the most important conceptual and technological advances in this area2–6, cools a beam through granular sampling and correction of its phase-space structure, thus bearing resemblance to a ‘Maxwell’s demon’. The extension of SC from the microwave regime up to optical frequencies and bandwidths has long been pursued, as it could increase the achievable cooling rates by three to four orders of magnitude and provide a powerful tool for future accelerators. First proposed nearly 30 years ago, optical stochastic cooling (OSC) replaces the conventional microwave elements of SC with optical-frequency analogues and is, in principle, compatible with any species of charged-particle beam7,8. Here we describe a demonstration of OSC in a proof-of-principle experiment at the Fermi National Accelerator Laboratory’s Integrable Optics Test Accelerator9,10. The experiment used 100-MeV electrons and a non-amplified configuration of OSC with a radiation wavelength of 950 nm, and achieved strong, simultaneous cooling of the beam in all degrees of freedom. This realization of SC at optical frequencies serves as a foundation for more advanced experiments with high-gain optical amplification, and advances opportunities for future operational OSC systems with potential benefit to a broad user community in the accelerator-based sciences. Stochastic cooling at optical frequencies is demonstrated in an experiment at the Fermi National Accelerator Laboratory’s Integrable Optics Test Accelerator, substantially increasing the bandwidth of stochastic cooling compared with conventional systems.
Collapse
Affiliation(s)
- J Jarvis
- Fermi National Accelerator Laboratory, Batavia, IL, USA.
| | - V Lebedev
- Fermi National Accelerator Laboratory, Batavia, IL, USA.
| | - A Romanov
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| | | | - K Carlson
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| | - S Chattopadhyay
- Fermi National Accelerator Laboratory, Batavia, IL, USA.,Department of Physics, Northern Illinois University, DeKalb, IL, USA.,SLAC National Accelerator Laboratory, Menlo Park, CA, USA
| | - A Dick
- Department of Physics, Northern Illinois University, DeKalb, IL, USA
| | - D Edstrom
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| | - I Lobach
- Department of Physics, The University of Chicago, Chicago, IL, USA
| | - S Nagaitsev
- Fermi National Accelerator Laboratory, Batavia, IL, USA.,Department of Physics, The University of Chicago, Chicago, IL, USA
| | - H Piekarz
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| | - P Piot
- Department of Physics, Northern Illinois University, DeKalb, IL, USA.,Argonne National Laboratory, Argonne, IL, USA
| | - J Ruan
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| | - J Santucci
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| | - G Stancari
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| | - A Valishev
- Fermi National Accelerator Laboratory, Batavia, IL, USA
| |
Collapse
|
10
|
Bei J, Xu G, Chang J, Wang X, Qiu D, Ruan J, Li X, Gao S. [SARS-CoV-2 with transcription regulatory sequence motif mutation poses a greater threat]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:399-404. [PMID: 35426804 DOI: 10.12122/j.issn.1673-4254.2022.03.12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To analyze the mutations in transcription regulatory sequences (TRSs) of coronaviruss (CoV) to provide the basis for exploring the patterns of SARS-CoV-2 transmission and outbreak. METHODS A combined evolutionary and molecular functional analysis of all sets of publicly available genomic data of viruses was performed. RESULTS A leader transcription regulatory sequence (TRS-L) usually comprises the first 60-70 nts of the 5' UTR in a CoV genome, and the body transcription regulatory sequences (TRS-Bs) are located immediately upstream of the genes other than ORF1a and 1b. In each CoV genome, the TRS-L and TRS-Bs share a specific consensus sequence, namely the TRS motif. Any changes of nucleotide residues in the TRS motifs are defined as TRS motif mutations. Mutations in the TRS-L or multiple TRS-Bs result in superattenuated variants. The spread of super-attenuated variants may cause an increase in asymptomatic or mild infections, prolonged incubation periods and a decreased detection rate of the viruses, thus posing new challenges to SARS-CoV-2 prevention and control. The super-attenuated variants also increase their possibility of long-term coexistence with humans. The Delta variant is significantly different from all the previous variants and may lead to a large-scale transmission. The Delta variant (B.1.617.2) with TRS motif mutation has already appeared and shown signs of spreading in Singapore, which, and even the Southeast Asia, may become the new epicenter of the next wave of SARS-CoV-2 outbreak. CONCLUSION TRS motif mutation will occur in all variants of SARS-CoV-2 and may result in super-attenuated variants. Only super-attenuated variants with TRS motif mutations will eventually lose the abilities of cross-species transmission and causing outbreaks.
Collapse
Affiliation(s)
- J Bei
- Agro-Biological Gene Research Center, Guangdong Academy of Agricultural Sciences, Guangzhou 510275, China
| | - G Xu
- College of Life Sciences, Nankai University, Tianjin 300071, China
| | - J Chang
- College of Life Sciences, Nankai University, Tianjin 300071, China
| | - X Wang
- School of Mathematical Sciences, Nankai University, Tianjin 300071, China
| | - D Qiu
- John Van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, United Kingdom
| | - J Ruan
- School of Mathematical Sciences, Nankai University, Tianjin 300071, China
| | - X Li
- College of Life Sciences, Nankai University, Tianjin 300071, China
| | - S Gao
- College of Life Sciences, Nankai University, Tianjin 300071, China
| |
Collapse
|
11
|
Drelichman GI, Fernández Escobar N, Soberon BC, Basack NF, Frabasil J, Schenone AB, Aguilar G, Larroudé MS, Knight JR, Zhao D, Ruan J, Mistry PK. Long-read single molecule real-time (SMRT) sequencing of GBA1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe skeletal phenotypes: Collaborative study from the Argentine Group for Diagnosis and Treatment of Gaucher Disease. Mol Genet Metab Rep 2021; 29:100820. [PMID: 34820281 PMCID: PMC8600149 DOI: 10.1016/j.ymgmr.2021.100820] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 11/05/2021] [Accepted: 11/05/2021] [Indexed: 10/27/2022] Open
Abstract
Gaucher disease is reckoned for extreme phenotypic diversity that does not show consistent genotype/phenotype correlations. In Argentina, a national collaborative group, Grupo Argentino de Diagnóstico y Tratamiento de la Enfermedad de Gaucher, GADTEG, have delineated uniformly severe type 1 Gaucher disease manifestations presenting in childhood with large burden of irreversible skeletal disease. Here using Long-Read Single Molecule Real-Time (SMRT) Sequencing of GBA1 locus, we show that RecNciI allele is highly prevalent and associates with severe skeletal manifestations in childhood.
Collapse
Affiliation(s)
- Guillermo I Drelichman
- Unidad de Hematología, Hospital de Niños "Ricardo Gutiérrez", Ciudad Autónoma de Buenos Aires, Argentina
| | - Nicolas Fernández Escobar
- Unidad de Hematología, Hospital de Niños "Ricardo Gutiérrez", Ciudad Autónoma de Buenos Aires, Argentina
| | - Barbara C Soberon
- Unidad de Hematología, Hospital de Niños "Ricardo Gutiérrez", Ciudad Autónoma de Buenos Aires, Argentina
| | - Nora F Basack
- Unidad de Hematología, Hospital de Niños "Ricardo Gutiérrez", Ciudad Autónoma de Buenos Aires, Argentina
| | - Joaquin Frabasil
- Laboratorio de Neuroquímica "Dr. N. A. Chamoles", Ciudad Autónoma de Buenos Aires, Argentina
| | - Andrea B Schenone
- Laboratorio de Neuroquímica "Dr. N. A. Chamoles", Ciudad Autónoma de Buenos Aires, Argentina
| | - Gabriel Aguilar
- Centro de Diagnóstico Dr. Rossi, Ciudad Autónoma de Buenos Aires, Argentina
| | - Maria S Larroudé
- Centro de Diagnóstico Dr. Rossi, Ciudad Autónoma de Buenos Aires, Argentina
| | - James R Knight
- Yale University Center for Genome Analysis, Yale School of Medicine, New Haven, CT, United States
| | - Dejian Zhao
- Yale University Center for Genome Analysis, Yale School of Medicine, New Haven, CT, United States
| | - Jiapeng Ruan
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT. United States
| | - Pramod K Mistry
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT. United States
| | | |
Collapse
|
12
|
Garcia Saldivia M, Ilarraza Lomeli H, Rojano Castillo J, Rius Suarez M, Franco M, Villegas D, Negrete D, Guerrero T, Sandoval C, Sanchez Cornejo A, Ruan J. Results of a hybrid cardiovascular rehabilitation program (in-hospital plus home) in patients with low income. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
One of the main problems facing cardiovascular rehabilitation (CR) is patient care and adherence. However, due to the low level of economic income of the patients who are cared for in our center, the possibility of going to CR in a conventional way is very difficult since they do not have the necessary resources to cover transportation, cost of the sessions, among others.
It has been shown that the greater the number of sessions attended by the patient, the greater the reduction in cardiovascular risk, however the role of a hybrid program with a decreased number of face-to-face sessions has not been established.
Purpose
Present the results of a hybrid training program (in-hospital plus home) in a low-income population. Education through supervised sessions plus home physical training in a patient with bases for exercise can improve their adherence with better results.
Methods
A cohort of patients with heart disease who were referred to the Cardiovascular Rehabilitation program between May 2017 and February 2019 was included. The socioeconomic level was classified into 6 strata according to occupation, income, housing, economic dependents, place of origin and family health status. After risk stratification, the patients participated in a hybrid program that consisted of 6 in-hospital sessions, once a week, in which the training to be carried out at home was prescribed by means of a triptych. An exercise test was performed before and after completing the program, as well as psychological and nutritional intervention. Statistical analysis was performed using SPSS 21.0 software. All p values less than 0.05 were considered significant.
Results
In the study period, of the total number of patients discharged for heart disease from the hospital, 61% were referred to cardiovascular rehabilitation, of which only 45% (n=39) completed the program, the reasons for dropping out were multiple and the lowest socioeconomic level (1) was the most frequent (figure 1). The main referral diagnosis was ischemic heart disease in 82%. The majority of patients were men, 95%. A significant improvement was observed in load METs, maximum heart rate, heart rate recovery (figure 2).
Conclusion
The implementation of a hybrid cardiovascular rehabilitation program (in-hospital + home) was associated with an improvement in the exercise test parameters of patients who successfully completed the program.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- M Garcia Saldivia
- Hospital Regional de Alta Especialidad de Ixtapaluca, Cardiac Rehabilitation, Ixtapaluca, Mexico
| | - H Ilarraza Lomeli
- National Institute of Cardiology Ignacio Chavez, Cardiac Rehabilitation, Mexico City, Mexico
| | - J Rojano Castillo
- National Institute of Cardiology Ignacio Chavez, Cardiac Rehabilitation, Mexico City, Mexico
| | - M Rius Suarez
- National Institute of Cardiology Ignacio Chavez, Cardiac Rehabilitation, Mexico City, Mexico
| | - M Franco
- National Institute of Cardiology Ignacio Chavez, Cardiac Rehabilitation, Mexico City, Mexico
| | - D Villegas
- Hospital Regional de Alta Especialidad de Ixtapaluca, Cardiac Rehabilitation, Ixtapaluca, Mexico
| | - D Negrete
- Hospital Regional de Alta Especialidad de Ixtapaluca, Cardiac Rehabilitation, Ixtapaluca, Mexico
| | - T Guerrero
- Hospital Regional de Alta Especialidad de Ixtapaluca, Cardiac Rehabilitation, Ixtapaluca, Mexico
| | - C Sandoval
- Hospital Regional de Alta Especialidad de Ixtapaluca, Cardiac Rehabilitation, Ixtapaluca, Mexico
| | - A Sanchez Cornejo
- Hospital Regional de Alta Especialidad de Ixtapaluca, Cardiac Rehabilitation, Ixtapaluca, Mexico
| | - J Ruan
- Hospital Regional de Alta Especialidad de Ixtapaluca, Cardiac Rehabilitation, Ixtapaluca, Mexico
| |
Collapse
|
13
|
Kleytman N, Ruan J, Ruan A, Zhang B, Murugesan V, Lin H, Guo L, Klinger K, Mistry PK. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease. Mol Genet Metab Rep 2021; 29:100798. [PMID: 34485083 PMCID: PMC8408524 DOI: 10.1016/j.ymgmr.2021.100798] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 08/24/2021] [Indexed: 11/28/2022] Open
Abstract
In Gaucher disease (GD), genetic deficiency of acid β-glucosidase leads to accumulation of its substrate glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). Lipid-laden cells, most prominently seen as macrophages engorged with GlcCer and GlcSph-laden lysosomes, trigger chronic metabolic inflammation and multisystemic phenotypes. Among the pleiotropic effects of inflammatory cascades, the induction of glucosylceramide synthase accentuates the primary metabolic defect. First-line therapies for adults with GD type 1 include Enzyme Replacement Therapy (ERT) and eliglustat Substrate Reduction Therapy (SRT). The ENCORE phase 3 clinical trial of eliglustat demonstrated non-inferiority compared to ERT. It is not known whether switching stable patients from long-term ERT to SRT results in the incremental reversal of the disease phenotype and its surrogate indicators. Herein, we report real-world experience from a single tertiary referral center of 38 adult GD type 1 patients, stable on long-term ERT (mean 13.3 years), who switched to eliglustat SRT (mean 3.1 years). After switch to SRT, there was significant reduction in spleen volume (P = 0.003) while liver volume, which was normal at baseline, remained unchanged. Platelet counts increased significantly (P = 0.026). Concomitantly, there was reduction of three validated biomarkers of Gaucher disease activity: plasma GlcSph decreased from 63.7 ng/ml (95% CI, 37.6-89.8) to 26.1 ng/ml (95% CI, 15.7-36.6) (P < 0.0001); chitotriosidase fell from 1136.6 nmol/ml/h (95% CI, 144.7-2128.6) to 466.9 nmol/ml/h (95% CI, 209.9-723.9) (P = 0.002); and glycoprotein non-metastatic melanoma B (gpNMB) decreased from 59.3 ng/ml (95% CI, 39.7-78.9) to 43.6 ng/ml (95% CI, 30.7-56.6) (P = 0.0006). There were no episodes of avascular necrosis or fractures in patients on SRT. Patients reported favorable experiences of switching from alternate week infusions to oral therapy. Collectively, these results demonstrate that the switch to eliglustat SRT from ERT leads to incremental response, even in stable patients after long-term ERT.
Collapse
Affiliation(s)
| | - Jiapeng Ruan
- Yale Internal Medicine: Digestive Diseases, New Haven, CT, USA
| | - Audrey Ruan
- Yale Internal Medicine: Digestive Diseases, New Haven, CT, USA
| | - Bailin Zhang
- Translational Sciences, Sanofi Genzyme, Cambridge, MA, USA
| | | | - Haiqun Lin
- Yale School of Public Health, New Haven, CT, USA
| | - Lilu Guo
- Translational Sciences, Sanofi Genzyme, Cambridge, MA, USA
| | | | - Pramod K Mistry
- Yale Internal Medicine: Digestive Diseases, New Haven, CT, USA
| |
Collapse
|
14
|
Ruan J, Zain JM, Palmer B, Jovanovic BB, Mi X, Swaroop A, Winter J, Gordon LI, Karmali R, Pro B. MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL). Hematol Oncol 2021. [DOI: 10.1002/hon.55_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Ruan
- Weill Cornell Medicine New York Presbyterian Hospital Medicine Hematology‐Oncology New York City, New York USA
| | - J. M Zain
- City of Hope Comprehensive Cancer Center, Medicine Duarte USA
| | - B. Palmer
- Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine, Medicine Chicago USA
| | - B. Borko Jovanovic
- Northwestern University Feinberg School of Medicine Department of Preventive Medicine Chicago USA
| | - X. Mi
- Northwestern University Feinberg School of Medicine Department of Preventive Medicine Chicago USA
| | - A. Swaroop
- Northwestern University Feinberg School of Medicine Department of Medicine Chicago USA
| | - J. Winter
- Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine, Medicine Chicago USA
| | - L. I Gordon
- Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine, Medicine Chicago USA
| | - R. Karmali
- Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine, Medicine Chicago USA
| | - B. Pro
- Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine, Medicine Chicago USA
| |
Collapse
|
15
|
Yuan GS, He WM, Hu XY, Li Q, Zang MY, Cheng X, Huang W, Ruan J, Wang JJ, Hou JL, Chen JZ. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study]. Zhonghua Gan Zang Bing Za Zhi 2021; 29:326-331. [PMID: 33979958 DOI: 10.3760/cma.j.cn501113-20210329-00148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To analyze the clinical efficacy and safety of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma (HCC). Methods: Ninety-four cases with mid-and advanced-stage HCC who received camrelizumab combined with apatinib as second-line treatment were enrolled. Routine blood test, blood biochemical indexes, tumor stage, tumor imaging characteristics, previous treatment strategies and other clinical data before treatment were documented. Imaging examination follow-up results and adverse reactions during treatment were followed up until the end of follow-up or loss of follow-up or death. Kaplan-Meier method was used to analyze the clinical efficacy. Results: As of the last follow-up, 94 cases with mid-and advanced-stage HCC had received camrelizumab combined with apatinib as second-line treatment. Among them, 15 cases were lost to follow-up, 31 cases died, and 48 cases survived. The overall remission rate was 31.9%. The overall disease control rate was 71.3%. The median time to disease-free progression was 6.6 months. The median time to disease progression was not yet available. The 1-year cumulative survival rate was 62.3%. Grade 3 and above adverse reactions mainly included were thrombocytopenia (7.4%), abdominal pain (4.3%), active hepatitis (4.3%), leukopenia (4.3%), diarrhea (3.2%), hand-foot syndrome (3.2%). All adverse reactions were effectively controlled. Conclusion: Camrelizumab combined with apatinib can effectively prolong the survival period of patients with mid-and advanced-stage HCC, and it is well tolerated.
Collapse
Affiliation(s)
- G S Yuan
- Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - W M He
- Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - X Y Hu
- Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Q Li
- Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - M Y Zang
- Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - X Cheng
- Department of Hepatology, Zengcheng Branch of Nanfang Hospital, Southern Medical University, Zengcheng 511300, China
| | - W Huang
- Department of Oncology, Shunde Hospital, Southern Medical University, Shunde 528300, China
| | - J Ruan
- Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China
| | - J J Wang
- Department of Infectious Disease, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
| | - J L Hou
- Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - J Z Chen
- Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
16
|
Ruan J, Ouyang M, Zhang W, Luo Y, Zhou D. The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma. Clin Transl Oncol 2020; 23:1134-1141. [PMID: 33211280 DOI: 10.1007/s12094-020-02499-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 09/15/2020] [Indexed: 12/31/2022]
Abstract
PURPOSE Our study aimed to explore the programmed death 1 (PD-1) expression on tumor-associated macrophage (TAM) in T cell non-Hodgkin lymphoma (T-NHL) and its relationship with lymphoma prognosis. The effect of PD-1 expression on the function of macrophages was also studied. METHODS Multispectral image quantitative analysis was applied for detecting PD-1 expression on macrophages in T cell lymphoma tissues. The Kaplan-Meier analysis was performed to evaluate the value of PD-1 expression of TAM in predicting the overall survival of T-NHL. PD-1 overexpression THP-1-derived macrophage was constructed and was cocultured with Jurkat cells to explore the effect of PD-1 on macrophage function. RESULTS In 17 T cell lymphoma cases, the 1-year overall survival rate was significantly lower in patients with higher PD-1 expression on TAMs (0.25 vs 0.86, p < 0.05). After co-cultured with Jurkat cells, classically activated (M1)-related markers on PD-1 overexpressed macrophages were significantly lower than those on controls, while the expressions of alternatively activated (M2) related markers were similar. The PD-1 overexpressed macrophages showed inhibited phagocytosis (4.42% vs 40.7%, p < 0.001) and increased IL-10 secretion (144.48 pg/ml vs 32.32 pg/ml, p < 0.001). CONCLUSION High PD-1 expression on TAMs in T-NHL may predict poor prognosis. The PD-1 overexpression of macrophages significantly inhibited polarization of M1 macrophages and phagocytosis, and more IL-10 was excreted. These changes may enhance the pro-tumor effects of tumor microenvironment.
Collapse
Affiliation(s)
- J Ruan
- Department of Hematology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China
| | - M Ouyang
- Department of Hematology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.,Department of Cardiovascule, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - W Zhang
- Department of Hematology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
| | - Y Luo
- Department of Immunology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China
| | - D Zhou
- Department of Hematology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China
| |
Collapse
|
17
|
Ruan Q, Xiao F, Gong K, Zhang W, Zhang M, Ruan J, Zhang X, Chen Q, Yu Z. Prevalence of Cognitive Frailty Phenotypes and Associated Factors in a Community-Dwelling Elderly Population. J Nutr Health Aging 2020; 24:172-180. [PMID: 32003407 DOI: 10.1007/s12603-019-1286-7] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVES Cognitive frailty was notable target for the prevention of adverse health outcomes in future. The goal of this study was to use a population-based survey to investigate cognitive frailty phenotypes and potentially sociodemographic factors in elderly Chinese individuals. DESIGN Cross-sectional study. SETTING General community. PARTICIPANTS A total of 5328 elderly adults (aged 60 years or older, mean age 71.36 years) enrolled in the Shanghai study of health promotion for elderly individuals with frailty. MEASUREMENTS The 5-item FRAIL scale and the 3-item Rapid Cognitive Screen tools were used to assess physical frailty and cognitive impairment, including dementia or mild cognitive impairment (MCI). Physical frailty was diagnosed by limitations in 3 or more of the FRAIL scale domains and pre-physical frailty by 1-2 limitations. Subjective cognitive decline (SCD) and pre-MCI SCD, was diagnosed with two self-report measures based on memory and other cognitive domains in elderly adults. RESULTS Of the participating individuals, 97.17% (n= 5177, female 53.4%) were eligible. Notably, 9.67%, 41.61% and 35.20% of participants were MCI, SCD and pre-MCI SCD; 35.86% and 4.41% exhibited physical pre-frailty and frailty; and 19.86% and 6.30% exhibited reversible and potential reversible cognitive frailty. Logistic regression analyses indicated that physical frailty phenotypes were significantly associated with MCI with SCD, and pre-MCI with SCD. Older single females with a high education level were more likely to exhibit the reversible cognitive frailty; and younger elderly individuals with a middle education level were at lower risk for potentially reversible cognitive frailty. CONCLUSIONS The prevalence of pre-physical and reversible cognitive frailty was high in elderly individuals and age was the most significant risk factor for all types of frailty phenotypes. To promote the rapid screening protocol of cognitive frailty in community-dwelling elderly is important to find high-risk population, implement effective intervention, and decrease adverse prognosis.
Collapse
Affiliation(s)
- Q Ruan
- Dr Zhuowei Yu, Shanghai Institute of Geriatrics and Gerontology, Shanghai Key Laboratory of Clinical Geriatrics, Department of Geriatrics, Huadong Hospital, and Research Center of Aging and Medicine, Shanghai Medical College, Fudan University, 221 West Yan An Road, Shanghai 200040, P.R. China, Tel: 86-21-62483180 Fax: 86-21-62484981
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Afinogenova Y, Ruan J, Yang R, Kleytman N, Pastores G, Lischuk A, Mistry PK. Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease. Mol Genet Metab 2019; 128:62-67. [PMID: 31358474 PMCID: PMC6864269 DOI: 10.1016/j.ymgme.2019.07.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 07/22/2019] [Accepted: 07/22/2019] [Indexed: 11/21/2022]
Abstract
In Gaucher disease, several macrophage-specific biomarkers have been validated for use in the clinic. However, Gaucher disease is more complex involving system-wide pathophysiology beyond the macrophage, and based on gene array analysis in our Gaucher disease mouse model and other emerging pathophysiologic insights, we evaluated serum levels of cathepsins D and S, YKL-40 and progranulin in Gaucher disease patients. We assessed their biomarker potential in Gaucher disease and compared them to established Gaucher disease biomarkers, chitotriosidase, chemokine ligand 18 (CCL18), and other indicators of disease severity and response to therapy. Mean YKL-40 and cathepsin D and S levels were significantly higher in Gaucher disease patients compared to healthy controls; in contrast, mean progranulin levels were lower in Gaucher disease patients compared to healthy controls. Enzyme replacement therapy resulted in a significant reversal of elevated cathepsin D and S but there was no change in progranulin and YKL-40 levels. Patients with persistent splenomegaly after long-term enzyme replacement therapy had significantly higher serum YKL-40 than patients with smaller spleens (63.0 ± 6.4 ng/ml vs. 46.4 ± 4.3 ng/ml, p = .03). Serum YKL-40 levels were higher in subjects with severe bone involvement (Hermann Score 3 to 5) compared to those with milder bone involvement (Hermann Score 1 to 2) (70.1 ± 4.3 ng/ml vs. 48.1 ± 3.7 ng/ml, p = .0002). YKL-40 was only weakly associated with chitotriosidase (r = 0.2, p = .008) and CCL18 (r = 0.3, p = .0004), and cathepsin S was moderately associated with chitotriosidase (r = 0.4, p = .01) and CCL18 (r = 0.6, p < .0001). Receiver operating curves for progranulin and YKL-40 demonstrated areas under the curves of 0.80 and 0.70, respectively. In conclusion, while these biomarkers do not meet robust properties of established macrophage-specific biomarkers, they may inform severity of skeletal disease, contribution of fibrosis to residual splenomegaly, and other disease manifestations. These findings, including markedly low progranulin levels that do not change upon enzyme replacement therapy, are intriguing to prompt further investigations to decipher their role in pathophysiology and relevance to diverse phenotypes of Gaucher disease.
Collapse
Affiliation(s)
- Yuliya Afinogenova
- Yale Department of Rheumatology, Allergy and Immunology, New Haven, CT, United States of America
| | - Jiapeng Ruan
- Yale Department of Digestive Diseases, New Haven, CT, United States of America
| | - Ruhua Yang
- Yale Department of Digestive Diseases, New Haven, CT, United States of America
| | - Nathaniel Kleytman
- Yale Department of Digestive Diseases, New Haven, CT, United States of America
| | - Gregory Pastores
- University College Dublin Department of Medicine, Dublin, Ireland
| | - Andrew Lischuk
- Yale Department of Musculoskeletal Radiology, New Haven, CT, United States of America
| | - Pramod K Mistry
- Yale Department of Digestive Diseases, New Haven, CT, United States of America.
| |
Collapse
|
19
|
Diaz C, Calderillo-Ruiz G, Ramos-Ramirez M, Herrera M, Manuel F, Horacio L, Ruiz-Garcia E, Itzel V, Ruan J, Miranda G, Gomez A, Meneses A. Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.342] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Ruan J, Leonard J, Coleman M, Rutherford S, Van Besien K, Rodriguez A, Benderoff L, Mehta-Shah N, Moskowitz A, Sokol L, Cerchietti L, Inghirami G, Martin P. MULTI-CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC-486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.8_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J. Ruan
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - J.P. Leonard
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - M. Coleman
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - S. Rutherford
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - K. Van Besien
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - A. Rodriguez
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - L. Benderoff
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - N. Mehta-Shah
- Department of Medicine; Washington University in St. Louis; St Louis United States
| | - A. Moskowitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - L. Sokol
- Department of Medicine; Moffitt Cancer Center; Tampa United States
| | - L. Cerchietti
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| | - G. Inghirami
- Department of Pathology; Weill Cornell Medical College; New York United States
| | - P. Martin
- Medicine/Hematology-Oncology; Weill Cornell Medical College; New York United States
| |
Collapse
|
21
|
Hu LI, Filippova EV, Dang J, Pshenychnyi S, Ruan J, Kiryukhina O, Anderson WF, Kuhn ML, Wolfe AJ. The spermidine acetyltransferase SpeG regulates transcription of the small RNA rprA. PLoS One 2018; 13:e0207563. [PMID: 30562360 PMCID: PMC6298664 DOI: 10.1371/journal.pone.0207563] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Accepted: 11/23/2018] [Indexed: 01/02/2023] Open
Abstract
Spermidine N-acetyltransferase (SpeG) acetylates and thus neutralizes toxic polyamines. Studies indicate that SpeG plays an important role in virulence and pathogenicity of many bacteria, which have evolved SpeG-dependent strategies to control polyamine concentrations and survive in their hosts. In Escherichia coli, the two-component response regulator RcsB is reported to be subject to Nε-acetylation on several lysine residues, resulting in reduced DNA binding affinity and reduced transcription of the small RNA rprA; however, the physiological acetylation mechanism responsible for this behavior has not been fully determined. Here, we performed an acetyltransferase screen and found that SpeG inhibits rprA promoter activity in an acetylation-independent manner. Surface plasmon resonance analysis revealed that SpeG can physically interact with the DNA-binding carboxyl domain of RcsB. We hypothesize that SpeG interacts with the DNA-binding domain of RcsB and that this interaction might be responsible for SpeG-dependent inhibition of RcsB-dependent rprA transcription. This work provides a model for SpeG as a modulator of E. coli transcription through its ability to interact with the transcription factor RcsB. This is the first study to provide evidence that an enzyme involved in polyamine metabolism can influence the function of the global regulator RcsB, which integrates information concerning envelope stresses and central metabolic status to regulate diverse behaviors.
Collapse
Affiliation(s)
- Linda I. Hu
- Department of Microbiology and Immunology, Loyola University Chicago, Health Sciences Division, Stritch School of Medicine, Maywood, IL, United States of America
| | - Ekaterina V. Filippova
- Center for Structural Genomics of Infectious Diseases, Northwestern University Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics, Chicago, IL, United States of America
| | - Joseph Dang
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, CA, United States of America
| | - Sergii Pshenychnyi
- Recombinant Protein Production Core at Chemistry of Life Processes Institute, Northwestern University, Chicago, IL, United States of America
| | - Jiapeng Ruan
- Center for Structural Genomics of Infectious Diseases, Northwestern University Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics, Chicago, IL, United States of America
| | - Olga Kiryukhina
- Center for Structural Genomics of Infectious Diseases, Northwestern University Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics, Chicago, IL, United States of America
| | - Wayne F. Anderson
- Center for Structural Genomics of Infectious Diseases, Northwestern University Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics, Chicago, IL, United States of America
| | - Misty L. Kuhn
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, CA, United States of America
| | - Alan J. Wolfe
- Department of Microbiology and Immunology, Loyola University Chicago, Health Sciences Division, Stritch School of Medicine, Maywood, IL, United States of America
- * E-mail:
| |
Collapse
|
22
|
Hanuka A, Santucci JK, Edstrom D, Schachter L, Ruan J. Amplification of flat laser pulse train. Opt Express 2018; 26:30818-30825. [PMID: 30469974 DOI: 10.1364/oe.26.030818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Accepted: 08/17/2018] [Indexed: 06/09/2023]
Abstract
We present modeling and measurements of flattop amplification of a laser pulse train in a diode pumped Nd:YLF system. We establish a theoretical model, accounting for the transverse Gaussian shape of an amplified laser beam, in order to explain remaining slopes in the pulse train energy. The influence of the transverse Gaussian shape on the train's flatness has been experimentally verified. Based on the model we are able to increase the total amplification of a long train of infrared seed beam in the drive laser system at the Fermilab Accelerator Science and Technology facility. The single-pass amplifier improvements resulted in a gain of ∼7 with flat output pulse train for up to 1000 seed pulses.
Collapse
|
23
|
Lykins JD, Filippova EV, Halavaty AS, Minasov G, Zhou Y, Dubrovska I, Flores KJ, Shuvalova LA, Ruan J, El Bissati K, Dovgin S, Roberts CW, Woods S, Moulton JD, Moulton H, McPhillie MJ, Muench SP, Fishwick CWG, Sabini E, Shanmugam D, Roos DS, McLeod R, Anderson WF, Ngô HM. CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii. Front Cell Infect Microbiol 2018; 8:352. [PMID: 30345257 PMCID: PMC6182094 DOI: 10.3389/fcimb.2018.00352] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 09/14/2018] [Indexed: 12/23/2022] Open
Abstract
Toxoplasma gondii, an Apicomplexan parasite, causes significant morbidity and mortality, including severe disease in immunocompromised hosts and devastating congenital disease, with no effective treatment for the bradyzoite stage. To address this, we used the Tropical Disease Research database, crystallography, molecular modeling, and antisense to identify and characterize a range of potential therapeutic targets for toxoplasmosis. Phosphoglycerate mutase II (PGMII), nucleoside diphosphate kinase (NDK), ribulose phosphate 3-epimerase (RPE), ribose-5-phosphate isomerase (RPI), and ornithine aminotransferase (OAT) were structurally characterized. Crystallography revealed insights into the overall structure, protein oligomeric states and molecular details of active sites important for ligand recognition. Literature and molecular modeling suggested potential inhibitors and druggability. The targets were further studied with vivoPMO to interrupt enzyme synthesis, identifying the targets as potentially important to parasitic replication and, therefore, of therapeutic interest. Targeted vivoPMO resulted in statistically significant perturbation of parasite replication without concomitant host cell toxicity, consistent with a previous CRISPR/Cas9 screen showing PGM, RPE, and RPI contribute to parasite fitness. PGM, RPE, and RPI have the greatest promise for affecting replication in tachyzoites. These targets are shared between other medically important parasites and may have wider therapeutic potential.
Collapse
Affiliation(s)
- Joseph D. Lykins
- Pritzker School of Medicine, University of Chicago, Chicago, IL, United States
| | - Ekaterina V. Filippova
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Andrei S. Halavaty
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - George Minasov
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Ying Zhou
- Department of Ophthalmology and Visual Sciences, University of Chicago, Chicago, IL, United States
| | - Ievgeniia Dubrovska
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Kristin J. Flores
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Ludmilla A. Shuvalova
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Jiapeng Ruan
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Kamal El Bissati
- Department of Ophthalmology and Visual Sciences, University of Chicago, Chicago, IL, United States
| | - Sarah Dovgin
- Illinois Math and Science Academy, Aurora, IL, United States
| | - Craig W. Roberts
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
| | - Stuart Woods
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
| | | | - Hong Moulton
- Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States
| | - Martin J. McPhillie
- Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, United Kingdom
| | - Stephen P. Muench
- School of Biomedical Sciences, Faculty of Biological Sciences, and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, United Kingdom
| | - Colin W. G. Fishwick
- School of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, United Kingdom
| | - Elisabetta Sabini
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | | | - David S. Roos
- Department of Biology, University of Pennsylvania, Philadelphia, PA, United States
| | - Rima McLeod
- Department of Ophthalmology and Visual Sciences, University of Chicago, Chicago, IL, United States
- Department of Pediatrics (Infectious Diseases), Institute of Genomics, Genetics, and Systems Biology, Global Health Center, Toxoplasmosis Center, CHeSS, The College, University of Chicago, Chicago, IL, United States
| | - Wayne F. Anderson
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Huân M. Ngô
- Center for Structural Genomics of Infectious Diseases and the Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
- BrainMicro LLC, New Haven, CT, United States
| |
Collapse
|
24
|
Liang J, Wu X, Sun S, Chen P, Liang X, Wang J, Ruan J, Zhang S, Zhang X. Circular RNA expression profile analysis of severe acne by RNA-Seq and bioinformatics. J Eur Acad Dermatol Venereol 2018; 32:1986-1992. [PMID: 29573483 DOI: 10.1111/jdv.14948] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Accepted: 03/01/2018] [Indexed: 12/29/2022]
Abstract
BACKGROUND Acne is a common chronic skin disease with a multifactorial aetiology and pathogenesis. Recently, circular RNAs (circRNAs) have been identified as a key factor in regulating gene expression through circRNA-miRNA-mRNA networks in many biological processes and human diseases. However, the circRNAs expression in patients with acne is still unknown. OBJECTIVE To investigate circRNA expression profile in severe acne. METHODS The expression profile of circRNAs in three paired lesional skin and adjacent non-lesional skin in severe acne was detected by high-throughput RNA sequencing technology and bioinformatics analysis. The candidate circRNAs were validated by PCR, Sanger sequencing and qRT-PCR in the separate group (n = 4). The circRNA-miRNA-mRNA interaction networks were predicted. RESULTS A total of 538 circRNAs including 271 up- and 267 downregulated circRNAs were differentially expressed in lesional skin compared with adjacent non-lesional skin in severe acne. Gene Ontology and KEGG pathway enrichment analyses revealed that the aberrantly expressed circRNAs were primarily involved in inflammatory, metabolism and immune responses. Five candidate circRNAs (circRNA_0084927, circRNA_0001073, circRNA_0005941, circRNA_0086376 and circRNA_0018168) were validated to have significant decrease in severe acne by PCR, Sanger sequencing and qRT-PCR, in agreement with the results from RNA-Seq data analysis. The five identified circRNAs were predicted to interact with 213 miRNAs and regulated target gene expression. CONCLUSION This study firstly showed that circRNAs were differentially expressed in severe acne and suggested that circRNAs could be used as a potential biomarker for the drug targets of acne.
Collapse
Affiliation(s)
- J Liang
- Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.,Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China
| | - X Wu
- BGI Genomics, BGI-Shenzhen, Shenzhen, China
| | - S Sun
- BGI Genomics, BGI-Shenzhen, Shenzhen, China
| | - P Chen
- Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - X Liang
- Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.,Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China
| | - J Wang
- Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.,Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China
| | - J Ruan
- Department of Dermatology, Jinan University Medical School Affiliated Hospital of Dongguan, Dongguan, China
| | - S Zhang
- Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.,Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China
| | - X Zhang
- Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.,Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China
| |
Collapse
|
25
|
Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 2017; 28:2806-2812. [PMID: 28945884 PMCID: PMC5789808 DOI: 10.1093/annonc/mdx496] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND This multicenter, phase II trial tested the tolerability and efficacy of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma (FL). PATIENTS AND METHODS Patients with grade 1-3a FL, stage 3-4 or bulky stage 2, FL international prognostic index (FLIPI) 0-2, and no prior therapy were eligible to receive rituximab 375 mg/m2 weekly during cycle 1 and day 1 of cycles 4, 6, 8, and 10, plus lenalidomide 20-25 mg on days 1-21 for twelve 28-day cycles. The primary objectives were to evaluate response rates [complete (CR) and overall] and time to progression. Secondary objectives included toxicity, response according to polymorphisms in FcgR2A and FcgR3A, and changes in circulating pro-angiogenic cells. RESULTS From October 2010 to September 2011, 66 patients were enrolled. Median age was 53 years, 34 were female, 15 had bulky disease, 21 were FLIPI 0-1, 43 FLIPI 2, and 2 FLIPI 3. One patient withdrew before receiving treatment. Fifty-one patients completed 12 cycles of lenalidomide. Reasons for discontinuation included withdrawal (n = 6), adverse events (n = 6), progression (n = 2). Grade 3-4 hematologic toxicity included neutropenia (21%), lymphopenia (9%), and thrombocytopenia (2%), infection (11%), and rash (8%). Grade 1-2 toxicity included fatigue (78%), diarrhea (37%), rash (32%), and febrile neutropenia in one patient. The overall response rate was 95%; the CR rate was 72% (95% confidence interval, 60% to 83%). With a median follow-up of 5 years, the 2- and 5-year progression-free survival were 86% and 70%, respectively, and the 5-year overall survival was 100%. There was no association between CR rate or PFS and FLIPI, histological grade, bulky disease, FcgR2A/FcgR3A polymorphism, or change in circulating endothelial cell/hematopoietic progenitor cell. CONCLUSION Lenalidomide plus rituximab was associated with low rates of grade 3-4 toxicity, yielded a CR rate and PFS similar to chemotherapy-based treatment and may represent a reasonable alternative to immunochemotherapy in previously untreated FL. CLINICALTRIALS.GOV IDENTIFIER NCT01145495.
Collapse
Affiliation(s)
- P Martin
- Department of Medicine, Weill Cornell Medicine, New York.
| | - S-H Jung
- Alliance Statistics and Data Center, Duke University Medical Center, Durham
| | - B Pitcher
- Alliance Statistics and Data Center, Duke University Medical Center, Durham
| | - N L Bartlett
- Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis
| | - K A Blum
- The Ohio State University Medical Center, Columbus
| | - T Shea
- Oncology, University of North Carolina at Chapel Hill, Chapel Hill
| | - E D Hsi
- Clinical Pathology, Cleveland Clinic, Cleveland
| | - J Ruan
- Department of Medicine, Weill Cornell Medicine, New York
| | - S E Smith
- Alliance Protocol Office, University of Chicago, Chicago
| | - J P Leonard
- Department of Medicine, Weill Cornell Medicine, New York
| | - B D Cheson
- Hematology/Oncology, Georgetown University Hospital, Washington, USA
| |
Collapse
|
26
|
Affiliation(s)
- Q. Ruan
- Shanghai Institute of Geriatrics and Gerontology, Shanghai Key Laboratory of Clinical Geriatrics, Department of Geriatrics, Huadong Hospital, and Research Center of Aging and Medicine, Shanghai Medical College, Fudan University, Shanghai 200040, China., Shanghai, China,
| | - L. Yang
- Department of anesthesiology Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, China
| | - J. Ruan
- Tongji medical college, Huazhong University of Science & Technology, Wuhan, China,
| | - W. Gu
- Department of anesthesiology Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, China,
| | - Y. Zhang
- Department of Gastroenterology, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, China,
| | - Z. Bao
- Shanghai Institute of Geriatrics and Gerontology, Shanghai Key Laboratory of Clinical Geriatrics, Department of Geriatrics, Huadong Hospital, and Research Center of Aging and Medicine, Shanghai Medical College, Fudan University, Shanghai 200040, China., Shanghai, China,
- Department of Gastroenterology, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, China,
| | - Z. Yu
- Shanghai Institute of Geriatrics and Gerontology, Shanghai Key Laboratory of Clinical Geriatrics, Department of Geriatrics, Huadong Hospital, and Research Center of Aging and Medicine, Shanghai Medical College, Fudan University, Shanghai 200040, China., Shanghai, China,
| |
Collapse
|
27
|
Martin P, Jung S, Pitcher B, Bartlett N, Blum K, Shea T, Ruan J, Smith S, Leonard J, Cheson B. FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Martin
- Medicine; Weill Cornell Medicine; New York USA
| | - S. Jung
- Alliance Statistics and Data Center; Duke University Medical Center; Durham USA
| | - B. Pitcher
- Alliance Statistics and Data Center; Duke University Medical Center; Durham USA
| | - N.L. Bartlett
- Medicine; Washington University School of Medicine; St. Louis USA
| | - K.A. Blum
- Medicine; The Ohio State University; Columbus USA
| | - T. Shea
- Medicine; University of North Carolina at Chapel Hill; Chapel Hill USA
| | - J. Ruan
- Medicine; Weill Cornell Medicine; New York USA
| | - S.E. Smith
- Alliance Protocol Office; University of Chicago; Chicago USA
| | | | - B.D. Cheson
- Medicine; Georgetown University Hospital; Washington D.C. USA
| |
Collapse
|
28
|
Rimm DL, McShane LM, Leung SCY, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere E, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga E, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M. Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-03-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The nuclear proliferation biomarker Ki67 has multiple potential roles in breast cancer, including prognosis-based decisions, but unacceptable between-laboratory variability has limited its clinical value. The International Ki67 Working Group (IKWG) has undertaken a systematic program to determine whether Ki67 immunohistochemistry can be analytically validated and standardized across laboratories. Technological advances and broader availability of devices for automated assessment of stained slides raise the possibility that these machines may improve on reproducibility of traditional pathologist-based visual Ki67 assessment.
Aims: To characterize reproducibility of automated machine-measured Ki67 expression using slides previously analyzed in the IKWG phase 3 study that evaluated reproducibility of visual Ki67 assessment.
Methods: Two sets of 30 previously stained slides containing core-cut biopsy sections of breast tumors were circulated to 14 laboratories for scanning and automated assessment of Ki67 expression. Sites were instructed to return average and maximum percentage of tumor cells positive for Ki67 for each slide, where maximum is designed to reflect “hot spot” analysis. Two laboratories returned scores from 2 operators; not all laboratories reported values for maximum Ki67 scores. Different operators were treated as distinct laboratories in analyses. Sixteen and 10 score sets were available for average and maximum Ki67 analyses, respectively, encompassing 7 unique scanner and 10 software platforms. Pre-specified analyses included evaluation of reproducibility across all laboratories as well as within a subgroup limited to those using Aperio scanners. The primary reproducibility metric was intraclass correlation coefficient between laboratories (ICC), regardless of device platform or software.
Results: Geometric means across 30 cases for 16 operators ranged from 11.06% to 38.11% with overall mean 16.75% (95% CI:14.45-19.42) for average scores. Geometric means for 10 operators ranged from 16.44% to 68.73% with overall mean 25.16% (95% CI: 18.71-33.84) for maximum scores. ICC for automated average scores across 16 operators was 0.83 (95% CI: 0.73-0.91) and ICC for maximum scores across 10 operators was 0.63 (95% CI: 0.44-0.80) although one outlier lab dramatically affected results. For the laboratories using the Aperio platform (8 score sets), ICC for automated average scores was 0.89 (95% CI; 0.81-0.96). These results are similar to ICC of 0.87 (95%CI; 0.81-0.93) reported using these same slides in the Phase 3 visual assessment reproducibility study in which observers counted 500 cells per slide (Leung et al, NPJBrCancer, in press).
Conclusions: Between-laboratory reproducibility for automated machine assessment of average Ki67 is similar to that for pathologist-based visual assessment of Ki67. However, the observed ICC was markedly numerically lower for the maximum score method compared to the average method, suggesting that the maximum score may not be useful as a reproducible measure of proliferation. Automated average scoring methods show promise for standardization of Ki67 scoring, supporting future studies to clinically validate Ki67.
Citation Format: Rimm DL, McShane LM, Leung SCY, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere E, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga E, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M. An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-03-01.
Collapse
Affiliation(s)
- DL Rimm
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - LM McShane
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - SCY Leung
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - Y Bai
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - AL Bane
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - JMS Bartlett
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - J Bayani
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - MC Chang
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - M Dean
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - C Denkert
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - E Enwere
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - C Galderisi
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - A Gholap
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - JC Hugh
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - A Jadhav
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - E Kornaga
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - A Laurinavicius
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - R Levenson
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - J Lima
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - K Miller
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - L Pantanowitz
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - T Piper
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - J Ruan
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - M Srinivasan
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - S Virk
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - Y Wu
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - H Yang
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - DF Hayes
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - TO Nielsen
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| | - M Dowsett
- Yale University School of Medicine, New Haven, CT; Biometric Research Branch, National Cancer Institute, Bethesda, MD; University of British Columbia, Vancouver, BC, Canada; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University of Alberta, Edmonton, AB, Canada; Institut für Pathologie, Charité Campus Mitte, Berlin, Germany; MolecularMD, Portland, OR; Optra Technologies, NeoPro SEZ, BlueRidge, Hinjewadi, India; National Center of Pathology, Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania; University of California Davis Medical Center, Sacramento, CA; Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, Dorset, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; Queen's University, K
| |
Collapse
|
29
|
Filippova EV, Wawrzak Z, Ruan J, Pshenychnyi S, Schultz RM, Wolfe AJ, Anderson WF. Crystal structure of nonphosphorylated receiver domain of the stress response regulator RcsB from Escherichia coli. Protein Sci 2016; 25:2216-2224. [PMID: 27670836 DOI: 10.1002/pro.3050] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 09/23/2016] [Accepted: 09/23/2016] [Indexed: 11/12/2022]
Abstract
RcsB, the transcription-associated response regulator of the Rcs phosphorelay two-component signal transduction system, activates cell stress responses associated with desiccation, cell wall biosynthesis, cell division, virulence, biofilm formation, and antibiotic resistance in enteric bacterial pathogens. RcsB belongs to the FixJ/NarL family of transcriptional regulators, which are characterized by a highly conserved C-terminal DNA-binding domain. The N-terminal domain of RcsB belongs to the family of two-component receiver domains. This receiver domain contains the phosphoacceptor site and participates in RcsB dimer formation; it also contributes to dimer formation with other transcription factor partners. Here, we describe the crystal structure of the Escherichia coli RcsB receiver domain in its nonphosphorylated state. The structure reveals important molecular details of phosphorylation-independent dimerization of RcsB and has implication for the formation of heterodimers.
Collapse
Affiliation(s)
- Ekaterina V Filippova
- Department of Biochemistry and Molecular Genetics, Center for Structural Genomics of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611
| | - Zdzislaw Wawrzak
- Life Science Collaborative Access Team, Synchrotron Research Center, Northwestern University, Argonne, Illinois, 60439
| | - Jiapeng Ruan
- Yale University School of Medicine, Department of Digestive Diseases, New Haven, CT 06510
| | - Sergii Pshenychnyi
- Recombinant Protein Production Core, Northwestern University, Chemistry of Life Processes Institute, Evanston, Illinois 60208
| | - Richard M Schultz
- Department of Microbiology and Immunology, Loyola University Chicago, Health Sciences Division, Stritch School of Medicine, Maywood, Illinois, 60153
| | - Alan J Wolfe
- Department of Microbiology and Immunology, Loyola University Chicago, Health Sciences Division, Stritch School of Medicine, Maywood, Illinois, 60153
| | - Wayne F Anderson
- Department of Biochemistry and Molecular Genetics, Center for Structural Genomics of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611
| |
Collapse
|
30
|
Wang HX, Zhang BQ, Lin JL, Song XC, Ruan J, Liu YO, He J, Sun ZH, Zhou WJ. [Functional mapping of the insular and opercular cortex: A study using SEEG electrical stimulation in epileptic patients]. Zhonghua Yi Xue Za Zhi 2016; 96:2347-51. [PMID: 27524194 DOI: 10.3760/cma.j.issn.0376-2491.2016.29.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE Insular and opercular cortex is involved in complicated physiological function.Insular seizures involve extensive epileptic network, which results in the complex and diverse semiology.Electrical cortical stimulation(ECS) can explore the functional mapping and symptomatogenic zone. METHODS The clinical presurgical evaluation and ECS data of 20 patients whose electrode contacts were located in the insular and opercular were analyzed retrospectively.CT scan/3D MRI data fusion was performed in order to accurately identify and locate each contact and check the electrode trajectory by the MRI images performed after the electrodes were removed.ECS was applied between two contiguous contacts.Stimulation usually lasted for 5 s at 50 Hz(pulse width=0.3 ms). Depending on the area of stimulated cortex, the stimulation intensities ranged from 0.2 to 3.0 mA.The classification of the insular were anterior short gyrus, middle short gyrus, precentral gyrus, postcentral gyrus, posterior long gyrus and insular pole.The classification of the opercular were orbital, frontal, precentral, central, parietal and temporal opercular. RESULTS One hundred and six contacts were located in the insular and 51 responses were evoked (48.11%). Four hundred eighteen contacts were located in the insular and 132 responses were evoked (31.58%). We classified the principal responses as somatosensory, pain, auditory, oropharyngeal, speech disturbances and neurovegetative response.Somatosensory responses were mainly evoked in parietal opercular and postcentral gyrus, while pain response distributed sporadically.Auditory were only evoked in temporal opercular(transverse temporal gyri) and posterior long gyrus.Oropharyngeal symptoms were only evoked in central opercular.Speech disturbances were located in precentral and central opercular and neurovegetative responses were mainly evoked in insular pole and middle short gyrus. CONCLUSIONS These findings may indicate a functional specificity for the insular gyrus and opercular, which contribute to the understanding of anatomo-functional organization and the role in insular and opercular epileptic network.Moreover, it could optimize the implantation strategy for exploring these structures.
Collapse
Affiliation(s)
- H X Wang
- Epilepsy Center, Yuquan Hospital, Tsinghua University, Beijing 100049, China
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ruan J, Shah B, Martin P, Schuster SJ. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. Ann Oncol 2016; 27:1226-34. [PMID: 27052651 DOI: 10.1093/annonc/mdw158] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 03/29/2016] [Indexed: 01/13/2023] Open
Abstract
Lenalidomide is an oral immunomodulatory drug with significant activity in indolent B-cell and mantle cell lymphomas. Lenalidomide has a manageable safety profile whether administered as a single agent or in combination with rituximab. The combination of lenalidomide with rituximab, known as the 'R(2)' regimen, enhances efficacy over what has been shown with monotherapy and has demonstrated activity in patients considered resistant to rituximab. Tolerability of these regimens has been consistent among studies. Asymptomatic neutropenia is the most common grade 3/4 adverse event, typically managed by dose interruption, followed by dose reduction once neutrophils have recovered. Nonhematologic toxicities (e.g. fatigue) are generally low-grade, manageable with concomitant treatment, and/or lenalidomide dose modification. More frequent with R(2), immune-related symptoms such as rash and tumor flare are important to recognize as lenalidomide-associated treatment effects in patients with lymphoma who require supportive care and potential dose modifications. Severe tumor flare reactions with painful lymphadenopathy are not typically observed outside of chronic lymphocytic leukemia/small lymphocytic lymphoma. Venous thromboembolism is uncommon in lymphomas, though prophylaxis is recommended. The general safety profile, differences between lenalidomide monotherapy and R(2) treatment, and optimal strategies for managing adverse events are discussed here.
Collapse
Affiliation(s)
- J Ruan
- Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York
| | - B Shah
- Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa
| | - P Martin
- Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York
| | - S J Schuster
- Division of Hematology and Medical Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA
| |
Collapse
|
32
|
Aigbirhio FI, Allwein S, Anwar A, Atzrodt J, Audisio D, Badman G, Bakale R, Berthon F, Bragg R, Brindle KM, Bushby N, Campos S, Cant AA, Chan MYT, Colbon P, Cornelissen B, Czarny B, Derdau V, Dive V, Dunscombe M, Eggleston I, Ellis-Sawyer K, Elmore CS, Engstrom P, Ericsson C, Fairlamb IJS, Georgin D, Godfrey SP, He L, Hickey MJ, Huscroft IT, Kerr WJ, Lashford A, Lenz E, Lewinton S, L'Hermite MM, Lindelöf Å, Little G, Lockley WJS, Loreau O, Maddocks S, Marguerit M, Mirabello V, Mudd RJ, Nilsson GN, Owens PK, Pascu SI, Patriarche G, Pimlott SL, Pinault M, Plastow G, Racys DT, Reif J, Rossi J, Ruan J, Sarpaki S, Sephton SM, Simonsson R, Speed DJ, Sumal K, Sutherland A, Taran F, Thuleau A, Wang Y, Waring M, Watters WH, Wu J, Xiao J. Abstracts of the 24th international isotope society (UK group) symposium: synthesis and applications of labelled compounds 2015. J Labelled Comp Radiopharm 2016; 59:175-86. [PMID: 26991121 DOI: 10.1002/jlcr.3377] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2015] [Accepted: 01/11/2016] [Indexed: 11/09/2022]
Abstract
The 24th annual symposium of the International Isotope Society's United Kingdom Group took place at the Møller Centre, Churchill College, Cambridge, UK on Friday 6th November 2015. The meeting was attended by 77 delegates from academia and industry, the life sciences, chemical, radiochemical and scientific instrument suppliers. Delegates were welcomed by Dr Ken Lawrie (GlaxoSmithKline, UK, chair of the IIS UK group). The subsequent scientific programme consisted of oral presentations, short 'flash' presentations in association with particular posters and poster presentations. The scientific areas covered included isotopic synthesis, regulatory issues, applications of labelled compounds in imaging, isotopic separation and novel chemistry with potential implications for isotopic synthesis. Both short-lived and long-lived isotopes were represented, as were stable isotopes. The symposium was divided into a morning session chaired by Dr Rebekka Hueting (University of Oxford, UK) and afternoon sessions chaired by Dr Sofia Pascu (University of Bath, UK) and by Dr Alan Dowling (Syngenta, UK). The UK meeting concluded with remarks from Dr Ken Lawrie (GlaxoSmithKline, UK).
Collapse
|
33
|
Ruan J, Mouveaux T, Light SH, Minasov G, Anderson WF, Tomavo S, Ngô HM. The structure of bradyzoite-specific enolase from Toxoplasma gondii reveals insights into its dual cytoplasmic and nuclear functions. Acta Crystallogr D Biol Crystallogr 2015; 71:417-26. [PMID: 25760592 PMCID: PMC4356359 DOI: 10.1107/s1399004714026479] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/12/2014] [Accepted: 12/01/2014] [Indexed: 12/15/2022]
Abstract
In addition to catalyzing a central step in glycolysis, enolase assumes a remarkably diverse set of secondary functions in different organisms, including transcription regulation as documented for the oncogene c-Myc promoter-binding protein 1. The apicomplexan parasite Toxoplasma gondii differentially expresses two nuclear-localized, plant-like enolases: enolase 1 (TgENO1) in the latent bradyzoite cyst stage and enolase 2 (TgENO2) in the rapidly replicative tachyzoite stage. A 2.75 Å resolution crystal structure of bradyzoite enolase 1, the second structure to be reported of a bradyzoite-specific protein in Toxoplasma, captures an open conformational state and reveals that distinctive plant-like insertions are located on surface loops. The enolase 1 structure reveals that a unique residue, Glu164, in catalytic loop 2 may account for the lower activity of this cyst-stage isozyme. Recombinant TgENO1 specifically binds to a TTTTCT DNA motif present in the cyst matrix antigen 1 (TgMAG1) gene promoter as demonstrated by gel retardation. Furthermore, direct physical interactions of both nuclear TgENO1 and TgENO2 with the TgMAG1 gene promoter are demonstrated in vivo using chromatin immunoprecipitation (ChIP) assays. Structural and biochemical studies reveal that T. gondii enolase functions are multifaceted, including the coordination of gene regulation in parasitic stage development. Enolase 1 provides a potential lead in the design of drugs against Toxoplasma brain cysts.
Collapse
Affiliation(s)
- Jiapeng Ruan
- Center for Structural Genomics of Infectious Diseases, Northwestern University, 320 E. Superior Street, Morton 7-601, Chicago, IL 60611, USA
| | - Thomas Mouveaux
- Center for Infection and Immunity of Lille, CNRS UMR 8204, INSERM U1019, Institut Pasteur de Lille, Université Lille Nord de France, France
| | - Samuel H. Light
- Center for Structural Genomics of Infectious Diseases, Northwestern University, 320 E. Superior Street, Morton 7-601, Chicago, IL 60611, USA
| | - George Minasov
- Center for Structural Genomics of Infectious Diseases, Northwestern University, 320 E. Superior Street, Morton 7-601, Chicago, IL 60611, USA
| | - Wayne F. Anderson
- Center for Structural Genomics of Infectious Diseases, Northwestern University, 320 E. Superior Street, Morton 7-601, Chicago, IL 60611, USA
| | - Stanislas Tomavo
- Center for Infection and Immunity of Lille, CNRS UMR 8204, INSERM U1019, Institut Pasteur de Lille, Université Lille Nord de France, France
| | - Huân M. Ngô
- Center for Structural Genomics of Infectious Diseases, Northwestern University, 320 E. Superior Street, Morton 7-601, Chicago, IL 60611, USA
- BrainMicro LLC, 21 Pendleton Street, New Haven, CT 06511, USA
| |
Collapse
|
34
|
Tonkin ML, Halavaty AS, Ramaswamy R, Ruan J, Igarashi M, Ngô HM, Boulanger MJ. Structural and functional divergence of the aldolase fold in Toxoplasma gondii. J Mol Biol 2014; 427:840-852. [PMID: 25284756 DOI: 10.1016/j.jmb.2014.09.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Revised: 08/27/2014] [Accepted: 09/23/2014] [Indexed: 10/24/2022]
Abstract
Parasites of the phylum Apicomplexa are highly successful pathogens of humans and animals worldwide. As obligate intracellular parasites, they have significant energy requirements for invasion and gliding motility that are supplied by various metabolic pathways. Aldolases have emerged as key enzymes involved in these pathways, and all apicomplexans express one or both of fructose 1,6-bisphosphate (F16BP) aldolase and 2-deoxyribose 5-phosphate (dR5P) aldolase (DERA). Intriguingly, Toxoplasma gondii, a highly successful apicomplexan parasite, expresses F16BP aldolase (TgALD1), d5RP aldolase (TgDERA), and a divergent dR5P aldolase-like protein (TgDPA) exclusively in the latent bradyzoite stage. While the importance of TgALD1 in glycolysis is well established and TgDERA is also likely to be involved in parasite metabolism, the detailed function of TgDPA remains elusive. To gain mechanistic insight into the function of different T. gondii aldolases, we first determined the crystal structures of TgALD1 and TgDPA. Structural analysis revealed that both aldolases adopt a TIM barrel fold accessorized with divergent secondary structure elements. Structural comparison of TgALD1 and TgDPA with members of their respective enzyme families revealed that, while the active-site residues are conserved in TgALD1, key catalytic residues are absent in TgDPA. Consistent with this observation, biochemical assays showed that, while TgALD1 was active on F16BP, TgDPA was inactive on dR5P. Intriguingly, both aldolases are competent to bind polymerized actin in vitro. Altogether, structural and biochemical analyses of T. gondii aldolase and aldolase-like proteins reveal diverse functionalization of the classic TIM barrel aldolase fold.
Collapse
Affiliation(s)
- Michelle L Tonkin
- Biochemistry and Microbiology, University of Victoria, PO Box 3055 STN CSC, Victoria, BC, Canada V8W 3P6
| | - Andrei S Halavaty
- Center for Structural Genomics of Infectious Diseases, Department of Biochemistry and Molecular Genetics, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
| | - Raghavendran Ramaswamy
- Biochemistry and Microbiology, University of Victoria, PO Box 3055 STN CSC, Victoria, BC, Canada V8W 3P6
| | - Jiapeng Ruan
- Center for Structural Genomics of Infectious Diseases, Department of Biochemistry and Molecular Genetics, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
| | - Makoto Igarashi
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, 2-13 Inada-cho, Obihiro, Hokkaido 080-8555, Japan
| | - Huân M Ngô
- Center for Structural Genomics of Infectious Diseases, Department of Biochemistry and Molecular Genetics, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA; BrainMicro LLC, 21 Pendleton Street, New Haven, CT 06511, USA
| | - Martin J Boulanger
- Biochemistry and Microbiology, University of Victoria, PO Box 3055 STN CSC, Victoria, BC, Canada V8W 3P6.
| |
Collapse
|
35
|
Ruan J, Liu XG, Zheng HL, Li JB, Xiong XD, Zhang CL, Luo CY, Zhou ZJ, Shi Q, Weng YG. Deletion of the lmna gene induces growth delay and serum biochemical changes in C57BL/6 mice. Asian-Australas J Anim Sci 2014; 27:123-30. [PMID: 25049934 PMCID: PMC4093278 DOI: 10.5713/ajas.2013.13246] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Revised: 08/28/2013] [Accepted: 07/27/2013] [Indexed: 01/03/2023]
Abstract
The A-type lamin deficient mouse line (Lmna−/−) has become one of the most frequently used models for providing insights into many different aspects of A-type lamin function. To elucidate the function of Lmna in the growth and metabolism of mice, tissue growth and blood biochemistry were monitored in Lmna-deficient mice, heterozygous (Lmna+/−) and wide-type (Lmna+/+) backcrossed to C57BL/6 background. At 4 weeks after birth, the weight of various organs of the Lmna−/−, Lmna+/− and Lmna+/+ mice was measured. A panel of biochemical analyses consisting of 15 serological tests was examined. The results showed that Lmna deficient mice had significantly decreased body weight and increased the ratio of organ to body weight in most of tissues. Compared with Lmna+/+ and Lmna+/− mice, Lmna−/− mice exhibited lower levels of ALP (alkaline phosphatase), Chol (cholesterol), CR (creatinine), GLU (glucose), HDL (high-density lipoprotein cholesterol) and higher levels of ALT (alanine aminotransferase) (p<0.05). Lmna−/− mice displayed higher AST (aspartate aminotransferase) values and lower LDL (lowdensity lipoprotein cholesterol), CK-MB (creatine kinase-MB) levels than Lmna+/+ mice (p<0.05). There were no significant differences among the three groups of mice with respect to BUN (blood urea nitrogen), CK (creatine kinase), Cyc C (cystatin C), TP (total protein), TG (triacylglycerols) and UA (uric acid) levels (p>0.05). These changes of serological parameters may provide an experimental basis for the elucidation of Lmna gene functions.
Collapse
Affiliation(s)
- J Ruan
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - X G Liu
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - H L Zheng
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - J B Li
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - X D Xiong
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - C L Zhang
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - C Y Luo
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - Z J Zhou
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - Q Shi
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| | - Y G Weng
- Department of Clinical Laboratory, Chongqing Medical University, Chongqing 400016, China
| |
Collapse
|
36
|
Kuhn ML, Prachi P, Minasov G, Shuvalova L, Ruan J, Dubrovska I, Winsor J, Giraldi M, Biagini M, Liberatori S, Savino S, Bagnoli F, Anderson WF, Grandi G. Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP. FASEB J 2014; 28:1780-93. [PMID: 24421400 DOI: 10.1096/fj.13-241737] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Despite the global medical needs associated with Staphylococcus aureus infections, no licensed vaccines are currently available. We identified and characterized a protein annotated as an epidermin leader peptide processing serine protease (EpiP), as a novel S. aureus vaccine candidate. In addition, we determined the structure of the recombinant protein (rEpiP) by X-ray crystallography. The crystal structure revealed that rEpiP was cleaved somewhere between residues 95 and 100, and we found that the cleavage occurs through an autocatalytic intramolecular mechanism. The protein expressed by S. aureus cells also appeared to undergo a similar processing event. To determine whether the protein acts as a serine protease, we mutated the hypothesized catalytic serine 393 residue to alanine, generating rEpiP-S393A. The crystal structure of this mutant protein showed that the polypeptide chain was not cleaved and was not interacting stably with the active site. Indeed, rEpiP-S393A was shown to be impaired in its protease activity. Mice vaccinated with rEpiP were protected from S. aureus infection (34% survival, P=0.0054). Moreover, the protective efficacy generated by rEpiP and rEpiP-S393A was comparable, implying that the noncleaving mutant could be used for vaccination purposes.
Collapse
Affiliation(s)
- Misty L Kuhn
- 2G.G., Novartis Vaccines, via Fiorentina 1, 53100, Siena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Shen J, Zheng H, Ruan J, Fang W, Li A, Tian G, Niu X, Luo S, Zhao P. Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. Br J Cancer 2013; 109:164-71. [PMID: 23799852 PMCID: PMC3708568 DOI: 10.1038/bjc.2013.306] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 05/21/2013] [Accepted: 05/24/2013] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Autophagy is a lysosomal degradation pathway that can provide energy through its recycling mechanism to act as a cytoprotective adaptive response mediating treatment resistance in cancer cells. We investigated the autophagy-inducing effects of ZD6474, a small-molecule inhibitor that blocks activities of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. METHODS We investigated the effects of ZD6474 on autophagy in glioblastomas cells. The ZD6474 mechanism of action was determined by western blot. We then examined the impacts of the inhibition of autophagy in combination with ZD6474 on cell apoptosis in vitro. Furthermore, we evaluated the synergistic anticancer activity of combination treatment with an autophagy inhibitor (chloroquine) and ZD6474 in U251 glioblastoma cells xenograft model. RESULTS ZD6474-induced autophagy was dependent on signalling through the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. ZD6474-induced autophagy was inhibited by both knockdown of the ATG7 and Beclin 1 gene, essential autophagy genes, and pharmacologic agents (chloroquine and 3-methyalanine) treatment. Both treatments also dramatically sensitised glioblastoma cells to ZD6474-induced apoptosis, decreasing cell viability in vitro. Furthermore, in a xenograft mouse model, combined treatment with ZD6474 and chloroquine significantly inhibited U251 tumour growth, and increased the numbers of apoptotic cells compared with treatment with either agent alone. CONCLUSION Autophagy protects glioblastoma cells from the proapoptotic effects of ZD6474, which might contribute to tumour resistance against ZD6474 treatment.
Collapse
Affiliation(s)
- J Shen
- Department of Cell Biology, Southern Medical University, Guangzhou, Gungdong, People's Republic of China
- Cancer Center, Southern Medical University, Guangzhou, Guangdong, People's Republic of China
| | - H Zheng
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China
| | - J Ruan
- Cancer Center, Southern Medical University, Guangzhou, Guangdong, People's Republic of China
| | - W Fang
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China
| | - A Li
- Cancer Center, Southern Medical University, Guangzhou, Guangdong, People's Republic of China
| | - G Tian
- Department of Cell Biology, Southern Medical University, Guangzhou, Gungdong, People's Republic of China
| | - X Niu
- Department of Cell Biology, Southern Medical University, Guangzhou, Gungdong, People's Republic of China
| | - S Luo
- Department of Cell Biology, Southern Medical University, Guangzhou, Gungdong, People's Republic of China
| | - P Zhao
- Cancer Center, Southern Medical University, Guangzhou, Guangdong, People's Republic of China
- Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China
| |
Collapse
|
38
|
|
39
|
He X, Ruan J, Du W, Chen G, Zuo X, Cao Y. PRM1 variant RS35576928 (R34S) was associated with defect spermatogenesis in the Chinese han population. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Ruan J. Antiangiogenic therapies in non-Hodgkin's lymphoma. Curr Cancer Drug Targets 2012; 11:1030-43. [PMID: 21933106 DOI: 10.2174/156800911798073014] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2011] [Revised: 09/18/2011] [Accepted: 09/18/2011] [Indexed: 11/22/2022]
Abstract
The tumor microenvironment is critical in the initiation and progression of cancerous growth, which is dependent on the establishment of a functional vascular network supporting neoplastic proliferation. While the precise role of tumor angiogenesis in lymphoma pathogenesis remains under active investigation, emerging data on the proangiogenic properties of the neoplastic lymphoma cells and mechanism of vascular assembly suggest that angiogenesis is highly relevant to the biology and therapy of non-Hodgkin's lymphoma. Antiangiogenic therapies in non-Hodgkin's lymphoma are in various stages of clinical development aiming at distinct angiogenic pathways operative in endothelial cells and perivascular stromal cells. The major classes of available antiangiogenics include anti-VEGF, small molecule inhibitors targeting proangiogenic receptor tyrosine kinases and their downstream signal transduction pathways, as well as immunomodulatory compounds with antiangiogenic properties. Preliminary clinical data indicate therapeutic advantages associated with strategies targeting dual compartments of vascular cells and tumor cells, as well as multiple angiogenic pathways within the tumor microenvironment. This review summarizes recent applications of antiangiogenic strategies in non-Hodgkin's lymphoma based on current understanding of the biology of lymphoma angiogenesis.
Collapse
Affiliation(s)
- J Ruan
- Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, USA.
| |
Collapse
|
41
|
Thangaraj J, Andonian G, Thurman-Keup R, Ruan J, Johnson AS, Lumpkin A, Santucci J, Maxwell T, Murokh A, Ruelas M, Ovodenko A. Demonstration of a real-time interferometer as a bunch-length monitor in a high-current electron beam accelerator. Rev Sci Instrum 2012; 83:043302. [PMID: 22559527 DOI: 10.1063/1.3698388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A real-time interferometer (RTI) has been developed to monitor the bunch length of an electron beam in an accelerator. The RTI employs spatial autocorrelation, reflective optics, and a fast response pyro-detector array to obtain a real-time autocorrelation trace of the coherent radiation from an electron beam thus providing the possibility of online bunch-length diagnostics. A complete RTI system has been commissioned at the A0 photoinjector facility to measure sub-mm bunches at 13 MeV. Bunch length variation (FWHM) between 0.8 ps (~0.24 mm) and 1.5 ps (~0.45 mm) has been measured and compared with a Martin-Puplett interferometer and a streak camera. The comparisons show that RTI is a viable, complementary bunch length diagnostic for sub-mm electron bunches.
Collapse
Affiliation(s)
- J Thangaraj
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Ruan J, Johnson AS, Lumpkin AH, Thurman-Keup R, Edwards H, Fliller RP, Koeth TW, Sun YE. First observation of the exchange of transverse and longitudinal emittances. Phys Rev Lett 2011; 106:244801. [PMID: 21770575 DOI: 10.1103/physrevlett.106.244801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2011] [Indexed: 05/31/2023]
Abstract
An experimental program to demonstrate a novel phase-space manipulation in which the horizontal and longitudinal emittances of a particle beam are exchanged has been completed at the Fermilab A0 Photoinjector. A new beam line, consisting of a TM(110) deflecting mode cavity flanked by two horizontally dispersive doglegs has been installed. We report on the first direct observation of transverse and longitudinal emittance exchange.
Collapse
Affiliation(s)
- J Ruan
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Wei B, Zhou Y, Xu Z, Ruan J, Zhu M, Jin K, Zhou D, Hu Q, Wang Q, Wang Z, Yan Z. XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 2011; 14:225-31. [PMID: 21647176 DOI: 10.1038/pcan.2011.26] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Epidemiological studies have evaluated the association between X-ray repair cross-complementing group 1 gene (XRCC1) Arg399Gln and Arg194Trp polymorphisms and risk of prostate cancer (PCa). However, the results from the published studies on the association between these two XRCC1 polymorphisms and PCa risk are conflicting. To derive a more precise estimation of association between the XRCC1 polymorphisms and risk of PCa, we performed a meta-analysis. A comprehensive search was conducted to identify all case-control studies of XRCC1 polymorphisms and PCa risk. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Overall, we found that both Arg399Gln and Arg194Trp polymorphisms were not significantly associated with PCa risk. However, in stratified analysis by ethnicity, we found that the Arg399Gln polymorphism was significantly associated with PCa risk in Asian population (Gln/Gln vs Arg/Arg: OR=1.46, 95% CI: 1.05-2.03, P=0.03; Gln/Gln vs Arg/Gln+Arg/Arg: OR=1.48, 95% CI: 1.12-1.95, P=0.01). In this meta-analysis, we found that both Arg399Gln and Arg194Trp polymorphisms were not related to overall PCa risk. However, in subgroup analysis we found a suggestion that XRCC1 399Gln allele might be a low-penetrent risk factor for PCa only in Asian men.
Collapse
Affiliation(s)
- B Wei
- Department of Urology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Bhushan B, Koinkar VN, Ruan J. Microtribological Studies by Using Atomic Force and Friction Force Microscopy and its Applications. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-332-93] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTWe have used atomic force microscopy (AFM) and friction force microscopy (FFM) techniques for microtribological studies including microscale friction, nanowear, nanoscratching and nanoindentation hardness measurements. The microscale friction studies on a gold ruler sample demonstrated that the local variation in friction correspond to a change of local surface slope, and this correlation is explained by a friction mechanism. Directionality effect is also observed as the sample was scanned in either direction. Nanoscratching, nanowear and nanoindentation hardness studies were performed on single-crystal silicon. Wear rates of single crystal silicon are approximately constant for various loads and test duration. Nanoindentation hardness studies show that AFM technique allows the hardness measurements of surface monolayers and ultra thin films in multilayered structures at very shallow depths and low loads. The AFM technique has also been shown to be useful for nanofabrication.
Collapse
|
45
|
Sun YE, Piot P, Johnson A, Lumpkin AH, Maxwell TJ, Ruan J, Thurman-Keup R. Tunable subpicosecond electron-bunch-train generation using a transverse-to-longitudinal phase-space exchange technique. Phys Rev Lett 2010; 105:234801. [PMID: 21231471 DOI: 10.1103/physrevlett.105.234801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Indexed: 05/30/2023]
Abstract
We report on the experimental generation of a train of subpicosecond electron bunches. The bunch train generation is accomplished using a beam line capable of exchanging the coordinates between the horizontal and longitudinal degrees of freedom. An initial beam consisting of a set of horizontally separated beamlets is converted into a train of bunches temporally separated with tunable bunch duration and separation. The experiment reported in this Letter unambiguously demonstrates the conversion process and its versatility.
Collapse
Affiliation(s)
- Y-E Sun
- Accelerator Physics Center, Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | | | | | | | | | | |
Collapse
|
46
|
Ruan J, Haerdter R, Gerendás J. Impact of nitrogen supply on carbon/nitrogen allocation: a case study on amino acids and catechins in green tea [Camellia sinensis (L.) O. Kuntze] plants. Plant Biol (Stuttg) 2010; 12:724-34. [PMID: 20701695 DOI: 10.1111/j.1438-8677.2009.00288.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
The concentrations of free amino acids (AA) and polyphenols (PP) are important determinants of green tea quality. Levels of AA and PP are governed interactively by nitrogen (N) supply and carbon (C) status, so the impact of C/N allocation on green tea quality was investigated in saplings cultivated hydroponically with 0.3, 0.75, 1.5 or 4.5 mmol l(-1) N. Activities of glutamine synthetase (GS), phenylalanine ammonia lyase (PAL), and phosphoenolpyruvate carboxylase (PEPC) were determined, as were concentrations of AA, PP and soluble sugars. Concentrations of AA increased with increasing N supply, and the AA profile was shifted towards AA characterised by low C/N ratios (arginine, glutamine) and away from theanine, the unique non-protein AA that is abundant in Camellia sinensis. High N supply significantly reduced the concentrations of PP in young shoots, and was accompanied by lower levels of carbohydrates (soluble sugars). Analysis of the C and N status and selected enzyme activities, combined with path coefficient analysis of variables associated with C and N metabolism, demonstrated increasing deviation of C flux to AA under abundant N supply. Accumulation of AA and PP depended strongly on N status, and the balance shifted toward increasing synthesis of AA associated with enhanced growth, while investment of C in secondary metabolites did not change proportionally under the condition of ample N supply.
Collapse
Affiliation(s)
- J Ruan
- Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, China.
| | | | | |
Collapse
|
47
|
Ruan J, Mark TM, Allan J, Morrison J, Koirala A, Martin P, Coleman M, Lachs M, Niesvizky R, Leonard JP. Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Thompson CA, Charlson ME, Schenkein E, Wells MT, Furman RR, Elstrom R, Ruan J, Martin P, Leonard JP. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010; 21:2262-2266. [PMID: 20423914 DOI: 10.1093/annonc/mdq215] [Citation(s) in RCA: 134] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND We aimed to assess anxiety and the psychological impact of routine surveillance scans in long-term survivors of adult aggressive lymphoma. PATIENTS AND METHODS In this cross-sectional observational study of 70 survivors of curable adult aggressive lymphoma, we measured anxiety and the doctor-patient relationship and performed a qualitative interview (n = 30) focused on patient perception of routine follow-up imaging studies. RESULTS Participants were diagnosed with aggressive lymphoma a median of 4.9 years (2.4-38.0 years) before enrollment. Thirty-seven percent of patients were found to meet criteria for clinically significant anxiety, which was not associated with years since diagnosis. In multivariate analysis, history of relapse and a worse doctor-patient relationship were independently associated with higher anxiety levels. Despite representing a largely cured population, in qualitative interviews patients reported fear of recurrence as a major concern and considerable anxiety around the time of a follow-up imaging scan. CONCLUSIONS Routine surveillance scans exacerbate underlying anxiety symptoms and fear of recurrence in survivors of aggressive lymphoma. Strategies to minimize follow-up imaging and to improve doctor-patient communication should be prospectively evaluated to address these clinically significant issues.
Collapse
Affiliation(s)
- C A Thompson
- Mayo Clinic, Department of Internal Medicine, Division of Hematology, Rochester, MN.
| | - M E Charlson
- Department of Internal Medicine, Division of General Internal Medicine
| | - E Schenkein
- Department of Internal Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York
| | - M T Wells
- Department of Statistical Science, Cornell University, Ithaca, NY, USA
| | - R R Furman
- Department of Internal Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York
| | - R Elstrom
- Department of Internal Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York
| | - J Ruan
- Department of Internal Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York
| | - P Martin
- Department of Internal Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York
| | - J P Leonard
- Department of Internal Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York
| |
Collapse
|
49
|
Huang Z, Richards MA, Zha Y, Francis R, Lozano R, Ruan J. Determination of inorganic pharmaceutical counterions using hydrophilic interaction chromatography coupled with a Corona CAD detector. J Pharm Biomed Anal 2009; 50:809-14. [PMID: 19616396 DOI: 10.1016/j.jpba.2009.06.039] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Revised: 06/18/2009] [Accepted: 06/19/2009] [Indexed: 12/01/2022]
Abstract
A simple generic approach was investigated for the determination of inorganic pharmaceutical counterions in drug substances using conventional high performance liquid chromatographic (HPLC) instruments. An intuitive approach combined Corona charged aerosol detection (CAD) with a polymer-based zwitterionic stationary phase in the hydrophilic interaction chromatography (HILIC) mode. Two generic methods based on this HILIC/CAD technique were developed to quantitate counterions such as Cl-, Br-, SO(4)(2-), K+, Ca2+ and Mg2+ in different pharmaceutical compounds. The development and capability of this HILIC/CAD technique analysis were examined. HILIC/CAD was compared to ion chromatography (IC), the most commonly used methodology for pharmaceutical counterion analysis. HILIC/CAD was found to have significant advantages in terms of: (1) being able to quantitate both anions and cations simultaneously without a need to change column/eluent or detection mode; (2) imposing much less restriction on the allowable organic percentage of the eluents than IC, and therefore being more appropriate for analysis of counterions of poorly water-soluble drugs; (3) requiring minimal training of the operating analysts. The precision and accuracy of counterion analysis using HILIC/CAD was not compromised. A typical precision of <2.0% was observed for all tested inorganic counterions; the determinations were within 2.0% relative to the theoretical counterion amount in the drug substance. Additionally, better accuracy was shown for Cl- in several drug substances as compared to IC. The main drawback of HILIC/CAD is its unsuitability for many of the current silica-based HILIC columns, because slight dissolution of silica leads to high baseline noise in the CAD detector. As a result of the universal detection characteristics of Corona CAD and the unique separation capabilities of a zwitterionic stationary phase, an intuitive and robust HPLC method was developed for the generic determination of various counterions in different drug substances. HILIC/CAD technique is a useful alternative methodology, particularly for determination of counterions in low-solubility drugs.
Collapse
Affiliation(s)
- Z Huang
- Bristol-Myers Squibb, Research and Development, 1 Squibb Drive, New Brunswick, NJ 08901, USA.
| | | | | | | | | | | |
Collapse
|
50
|
Ruan J, Martin P, Coleman M, Furman R, Glynn P, Joyce M, Cheung K, Shore T, Schuster M, Leonard J. Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8525 Background: Targeting tumor microenvironment and angiogenesis is a novel therapeutic strategy in lymphoma. Two putative anti-angiogenic regimens, RT (rituximab with thalidomide) and PEPC oral metronomic chemotherapy (prednisone, etoposide, procarbazine and cyclophosphamide) are clinically active. We report phase II safety, activity, and angiogenic profiling data with the novel combination RT-PEPC in elderly patients with recurrent MCL. Methods: RT-PEPC includes an induction phase (mo 1–3) of daily thalidomide (50 mg) and PEPC with weekly rituximab x 4. A maintenance phase (mo 4 until progression) continues with daily thalidomide (100 mg), PEPC dosing titrated to ANC > 1K/ul, and rituximab q 4 months. Endpoints included safety, efficacy, and FACT-G quality of life (QoL) assessment. Translational studies assessed the angiogenic phenotypes of tumor cells, and dynamic levels of circulating endothelial and hematopoietic progenitors in response to treatment. Results: Twenty-five pts (19 males) were enrolled, with 22 evaluable (3 never received rx). At study entry, median age (N=25) was 68 yrs (range 52–81), 24 (96%) had stage ≥ III, 16 (64%) had LDH > nl, and 18 (72%) IPI 3–5. The median number of prior therapies was two (range 1 to 7), and 15 pts (60%) progressed on bortezomib. At a median followup of 30 months, overall response rate was 73% (32% CR/CRu, 41% PR, N=22). Median PFS was 12 months, and median OS 22 months. Four CRs of 4+, 28+, 46+ and 48+ months are ongoing. Toxicities included gr 1–2 fatigue, rash and neuropathy as well as cytopenias (by design) including gr 1–2 thrombocytopenia (56%) and gr 3/4 neutropenia (56%). Two thrombotic events and 5 episodes of gr 3–4 infection were observed. QoL was maintained or improved on treatment. Correlative studies demonstrated pre-therapy autocrine angiogenic loop in tumor cells evidenced by expression of VEGFA and VEGFR1. Circulating levels of hematopoietic and endothelial progenitor cells decreased on rx in responders. Conclusions: RT-PEPC has significant and durable clinical activity in MCL, with manageable toxicity and maintained QoL. Novel low-intensity anti-angiogenic approaches warrant further evaluation in MCL and other NHL subtypes, potentially as initial therapy in elderly patients. [Table: see text]
Collapse
Affiliation(s)
- J. Ruan
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - P. Martin
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - M. Coleman
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - R. Furman
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - P. Glynn
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - M. Joyce
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - K. Cheung
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - T. Shore
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - M. Schuster
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| | - J. Leonard
- Weill Cornell Medical College, New York, NY; Columbia University, New York, NY
| |
Collapse
|